Eric Murphy

Eric Murphy

Company: Kinnate Biopharma Inc.

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Panel Discussion – Clinical Program Development Takeaways: How Can Researchers & Drug Developers in Any Targeted, Immune, Chemo, ADC Therapies Unite & Collaborate Future Directions to Optimize Our Own Drugs & Overall Patient Outlook? 11:30 am

Learnings from the past, how have we each developed our drugs considering previous work published? How can we optimize our program for any of the GI Cancer Indications? Thoughts on translating an established candidate from another solid tumor into GI cancer Utilizing patient groups, precision oncology & early detection in our clinical programsRead more

day: Day Two

FGFR2 Fusions: Addressing Clinically Relevant Secondary Mutations 9:00 am

FGFR2 alterations are known oncogenic drivers in intrahepatic cholangiocarcinoma (iCCA) with fusions or rearrangements detected in > 10% of patients Preclinical studies with KIN-3248, an irreversible pan-FGFR inhibitor, demonstrate inhibition across the full spectrum of clinically relevant FGFR2 secondary resistance mutations observed in iCCA Duration of response may be improved by targeting known FGFR2 secondary…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.